In short
Clinical trials are investigating VALACICLOVIR HYDROCHLORIDE in people with HSV-2 meningitis. These studies aim to see whether treatment helps improve outcomes and how it compares with placebo. The main focus is on safety and effectiveness in adults with this infection.
Key points
- Clinical trials of VALACICLOVIR HYDROCHLORIDE in the provided data focus on HSV-2 meningitis, a viral infection that affects the lining around the brain and spinal cord. The main study is a Phase 3, randomised, double-blinded trial with 150 planned participants. It compares active treatment with placebo to see whether treatment improves patient outcomes. The main endpoint is the proportion of patients with a Total Morbidity Score above 6 at 7 days after randomisation. The trial is designed to test whether active treatment with (val)acyclovir is superior to placebo for viral meningitis.
Trial overview
The provided trial data include one interventional study of VALACICLOVIR HYDROCHLORIDE for people with HSV-2 meningitis. The study is titled “Aciclovir for HSV-2 MENingitis: A double-blinded randomised controlled trial (AMEN),” and it is authorised. Its brief summary says the researchers want to see whether active treatment with (val)acyclovir is better than placebo for viral meningitis.
Study design and phase
This is a Phase 3 trial, which means it is a later-stage study meant to test how well the treatment works in a patient group. It is a randomised controlled trial, so participants are assigned by chance to different study groups. The study is also double-blinded, which means the patient and the study team do not know who receives active treatment or placebo.
Who is being studied
The target condition in this trial is HSV-2 meningitis. The source data do not list all inclusion or exclusion rules, but the study is clearly aimed at patients with this diagnosis. The planned enrollment is 150 participants, which gives an idea of the study size.
What the trial measures
The primary outcome is the proportion of patients with a Total Morbidity Score (TMS) greater than 6 at 7 days after randomisation. In simple terms, the researchers are checking how many patients still have a higher illness burden one week after the study starts. This endpoint helps show whether the treatment leads to better short-term recovery compared with placebo.
Placebo and blinding
The interventions listed include active intravenous aciclovir, oral VALACICLOVIR HYDROCHLORIDE, and matching placebo products. The placebo tablets and placebo intravenous treatment are made to look like the active products, which helps keep the comparison fair. Because the study is double-blinded, the results are less likely to be influenced by expectations from patients or researchers.
Trial summary
In the available data, VALACICLOVIR HYDROCHLORIDE is being studied in one Phase 3 trial for HSV-2 meningitis. The study asks whether active treatment is superior to placebo and uses a short-term clinical score as the main outcome. The trial is authorised, randomised, and double-blinded, with 150 planned participants.